Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study When Metformin Hydrochloride 500 mg is Added on to SYR-322 25 mg in Type 2 Diabetic Patients

NCT02068443 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02068443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02068443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study When Metformin Hydrochloride 500 mg is Added on to SYR-322 25 mg in Type 2 Diabetic Patients
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2014
Completion date
February 28, 2015
Enrollment
374 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus